Forian (NASDAQ:FORA - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at Roth Mkm in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $5.00 price target on the stock. Roth Mkm's target price suggests a potential upside of 146.31% from the stock's previous close.
Forian Stock Performance
Shares of FORA traded down $0.01 on Thursday, reaching $2.03. The stock had a trading volume of 41,545 shares, compared to its average volume of 15,846. The firm has a market capitalization of $63.16 million, a price-to-earnings ratio of 40.60 and a beta of 1.09. The company has a 50-day simple moving average of $2.14 and a 200-day simple moving average of $2.44. Forian has a 12-month low of $2.00 and a 12-month high of $4.15.
Forian (NASDAQ:FORA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06). The company had revenue of $4.78 million for the quarter, compared to the consensus estimate of $5.26 million. During the same quarter last year, the business earned ($0.03) earnings per share.
Hedge Funds Weigh In On Forian
A number of institutional investors and hedge funds have recently modified their holdings of FORA. Elser Financial Planning Inc purchased a new position in Forian in the second quarter worth about $1,885,000. Caprock Group LLC purchased a new stake in Forian during the second quarter valued at approximately $230,000. Finally, Canton Hathaway LLC raised its position in Forian by 2.3% in the third quarter. Canton Hathaway LLC now owns 269,650 shares of the company's stock worth $582,000 after acquiring an additional 6,125 shares during the period. 19.25% of the stock is currently owned by hedge funds and other institutional investors.
About Forian
(
Get Free Report)
Forian Inc provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the healthcare and related industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions.
Featured Articles
Before you consider Forian, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Forian wasn't on the list.
While Forian currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
